Drug Profile
TH 9229
Alternative Names: ProtectazemLatest Information Update: 06 Nov 2006
Price :
$50
*
At a glance
- Originator Theratechnologies
- Class Anti-ischaemics; Cardiotonics
- Mechanism of Action Platelet activating factor inhibitors; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Myocardial infarction
Most Recent Events
- 06 Nov 2006 Discontinued - Preclinical for Angina pectoris in Canada (unspecified route)
- 06 Nov 2006 Discontinued - Preclinical for Myocardial infarction in Canada (unspecified route)
- 11 Oct 2002 No development reported - Preclinical for Angina pectoris in Canada (unspecified route)